Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00580983 · ClinicalTrials.gov registry record · NA

Optimized Intensity Modulated Irradiation for Head and Neck Cancer

A NA study, sponsored by University of Michigan Rogel Cancer Center.

Completed
Registry status
NA
Development phase
90
Enrollment target

NCT00580983 is a NA study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 90 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00580983, a NA study, has completed, sponsored by University of Michigan Rogel Cancer Center.

COMPLETED
Registry status
NA
Development phase
90 participants
Enrollment target

Study Summary

The purpose of this study is to test whether the use of advanced radiation therapy delivery techniques can spare a patient's normal tissue, including salivary glands, from radiation. This study is being done to try to reduce radiation side effects, especially mouth dryness, which happens with standard radiation methods. In order to reduce these side effects, other normal tissues may receive a different radiation dose (sometimes more) than what would have been received using standard radiation therapy. A secondary goal of this study is to determine if the type of tumor a patient has can be controlled at least as well (or better) using this advanced radiation therapy delivery technique as it would be if the patient was treated with standard radiation therapy.

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Paclitaxel
  • DRUG 5-Fluorouracil
  • RADIATION IMRT

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2003-08
Est. Completion 2010-06
Phase NA

What the Registry Record Tells You About NCT00580983

The ClinicalTrials.gov registry entry for NCT00580983 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.

NCT00580983 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00580983 about?

NCT00580983 is a clinical study titled "Optimized Intensity Modulated Irradiation for Head and Neck Cancer". The purpose of this study is to test whether the use of advanced radiation therapy delivery techniques can spare a patient's normal tissue, including salivary glands, from radiation. This study is being done to try to reduce radiation side effects, especially mouth dryness, which happens with standa...

What is the current status of trial NCT00580983?

This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2003-08. Estimated completion is 2010-06.

What interventions are being tested in trial NCT00580983?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG), 5-Fluorouracil (DRUG), IMRT (RADIATION).

Who is sponsoring clinical trial NCT00580983?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.